GSK And Google To Invest £540m In UK-Headquartered Bioelectronics JV
GlaxoSmithKline is teaming up with the company formerly known as Google Life Sciences to create bioelectronic therapeutics, and hopes to have a product ready for market within seven years.
You may also be interested in...
Biopharma executives and investors gathered in San Diego on Feb. 28 and March 1 to talk about finding and funding innovation with a focus on novel technology and artificial intelligence that can improve drug discovery and development success rates.
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
As the pharmaceutical industry works to manage big data, improve the way drugs are used and delivered, and expand services to patients, industry is working increasingly with non-traditional partners.